• CAY10499: Inhibitor of Human Hormone Sensitive Lipase in Lip

  2026-07-23

  CAY10499, a potent inhibitor of human hormone sensitive lipase, enables precise dissection of lipid-driven immunometabolic processes. Its nanomolar potency and selectivity empower researchers to unravel complex lipid signaling in tumor microenvironments and metabolic disease models.

• GlycoRNA-RBP Nanoclusters Enable Cell Penetrating Peptide En

  2026-07-23

  The referenced study uncovers that RNA binding proteins (RBPs) and glycoRNAs form discrete nanoclusters on the cell surface, which act as entry points for cell penetrating peptides (CPPs) like TAT. This finding revises cell surface biology, highlighting new targets for mapping extracellular interactomes and improving delivery technologies.

• Ferroptosis Inducers as a Novel Strategy for Advanced Prosta

  2026-07-22

  This study demonstrates that ferroptosis inducers, including Erastin, significantly impair growth and migration of treatment-resistant prostate cancer cells in vitro and delay tumor progression in vivo. The findings support the potential of ferroptosis-targeting compounds, alone or in combination with anti-androgens, as promising new therapeutic strategies for advanced prostate cancer.

• Redefining Cre Recombinase mRNA Delivery for Extrahepatic Ed

  2026-07-22

  This thought-leadership article explores the evolution of Cre recombinase mRNA delivery, emphasizing the transformative potential of m1Ψ- and Cap 1-modified mRNAs—such as EZ Cap™ Cre mRNA (m1Ψ)—in overcoming extrahepatic targeting and immune activation barriers. Drawing on recent advances in virus-mimicking particle design, it provides strategic guidance for translational researchers aiming to achieve high-efficiency, low-immunogenicity gene editing across diverse tissues.

• Firefly Luciferase mRNA: Enhanced Assays with 5-moUTP Modifi

  2026-07-21

  EZ Cap™ Firefly Luciferase mRNA (5-moUTP) delivers robust, immune-evasive bioluminescent reporter expression for gene regulation and translation efficiency studies. Its advanced 5-moUTP and Cap1 modifications translate into higher stability, superior protein yield, and reduced innate immune activation—making it an essential tool for both in vitro and in vivo research workflows.

• EGCG: Mechanistic Innovations and Translational Barriers in

  2026-07-21

  Explore the multifaceted roles of (-)-Epigallocatechin gallate (EGCG) in apoptosis, antiangiogenesis, and antimicrobial research. This in-depth article uncovers EGCG's mechanistic challenges and translational hurdles, providing new insights beyond standard workflows.

• VE-822 ATR Inhibitor: Precision Tools for DNA Damage Respons

  2026-07-20

  VE-822, a potent ATR inhibitor from APExBIO, empowers researchers to dissect DNA damage response and drive radiosensitization in challenging models like pancreatic ductal adenocarcinoma. This guide delivers practical workflows, troubleshooting insights, and actionable protocol parameters for integrating VE-822 into state-of-the-art cancer research and iPSC-based platforms.

• Adefovir (GS-0393): Advanced Insights into Antiviral Mechani

  2026-07-20

  Explore the molecular antiviral mechanism of Adefovir (GS-0393) and its unique role in hepatitis B virus research. This article offers a deeper scientific analysis and highlights critical safety findings that influence experimental design.

• Lamotrigine in Epilepsy & Cardiac Research: Applied Workflow

  2026-07-19

  Lamotrigine (6-(2,3-dichlorophenyl)-1,2,4-triazine-3,5-diamine) stands out for precise sodium channel and serotonin pathway modulation in epilepsy and cardiac studies. This guide details optimized protocols, troubleshooting strategies, and unique assay opportunities enabled by APExBIO's high-purity Lamotrigine.

• Nitrocefin in Precision β-Lactamase Inhibitor Discovery

  2026-07-18

  Explore how Nitrocefin, a chromogenic cephalosporin substrate, is transforming β-lactamase enzymatic activity measurement and accelerating the rational discovery of novel inhibitors. This article delivers advanced insights into assay optimization and the latest in silico screening breakthroughs.

• Bradford Protein Assay Kit: Technical Guide for Accurate Pro

  2026-07-17

  The Bradford Protein Assay Kit (SKU K4103) delivers rapid and sensitive protein concentration measurement for research workflows. It is optimal for samples without interfering substances such as detergents. For accurate results, avoid use in applications where interfering chemicals may impact dye binding.

• Camptothecin (SKU A2877): Reliable DNA Damage Inducer for La

  2026-07-17

  This article provides evidence-based guidance for biomedical researchers on leveraging Camptothecin (SKU A2877) as a robust topoisomerase I inhibitor in cell-based assays. Scenario-driven Q&As address experimental design, optimization, data interpretation, and product selection, highlighting why APExBIO’s Camptothecin is a preferred choice for reproducible DNA damage and autophagy studies.

• Mithramycin A: Integrative Insights for Cancer and Gene Regu

  2026-07-16

  Discover how Mithramycin A, an anticancer antibiotic, enables advanced study of transcriptional regulation and c-myc inhibition in cancer biology. This article uncovers unique assay implications and bridges mechanistic understanding with practical research design.

• Monomethyl auristatin E (MMAE): Reliable Cytotoxicity Assays

  2026-07-16

  This authoritative article addresses common laboratory challenges in cytotoxicity and antibody-drug conjugate (ADC) workflows, presenting Monomethyl auristatin E (MMAE, SKU A3631) as a data-backed solution. Grounded in peer-reviewed evidence, it guides researchers on protocol optimization, vendor selection, and robust data interpretation, emphasizing the reproducibility and potency of MMAE.

• Reliable Gene Editing with EZ Cap™ Cre mRNA (m1Ψ): Lab Scena

  2026-07-15

  This article examines real laboratory challenges in gene editing, focusing on how EZ Cap™ Cre mRNA (m1Ψ) (SKU R1030) delivers reproducible, low-immunogenicity Cre recombinase expression for cell assays. Through scenario-driven Q&A, we highlight evidence-based protocol improvements, comparative reliability, and practical workflow guidance for researchers seeking robust results.

16719 records 1/1115 page Next 12345 下5页 Last page